Evidence map›Paper›PMID 41678086›Full record

Trial reportAnnals of nuclear medicine2026

Long-term efficacy and safety of peptide receptor radionuclide therapy in Japanese patients with unresectable neuroendocrine tumor: extension of the Japanese phase I and phase I/II study.

Noritoshi Kobayashi, Hiroaki Ono, Naoki Okubo, Keiichi Akahoshi, Atsushi Kudo, Daisuke Ban, Yasushi Ichikawa

Abstract readClinical Trial, Phase IClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Noritoshi KobayashiDepartment of Oncology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura Kanazawa-ku, Yokohama, 236-0004, Japan. norikoba@yokohama-cu.ac.jp.ORCID http://orcid.org/0000-0002-9181-3722
Hiroaki OnoDepartment of Hepatobiliary and Pancreatic Surgery, Institute of Science Tokyo, Tokyo, Japan.
Naoki OkuboDepartment of Oncology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura Kanazawa-ku, Yokohama, 236-0004, Japan.
Keiichi AkahoshiDepartment of Hepatobiliary and Pancreatic Surgery, Institute of Science Tokyo, Tokyo, Japan.
Atsushi KudoDepartment of Hepatobiliary and Pancreatic Surgery, Institute of Science Tokyo, Tokyo, Japan.
Daisuke BanDepartment of Hepatobiliary and Pancreatic Surgery, Institute of Science Tokyo, Tokyo, Japan.
Yasushi IchikawaDepartment of Oncology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura Kanazawa-ku, Yokohama, 236-0004, Japan.

Funding

Novartis Pharma K.K. CABC123DJP01T
6 · The paper itself

Abstract

objectivePeptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogs is an innovative treatment for advanced well-differentiated neuroendocrine tumors (NETs). In Japan, PRRT with Lutetium-177 oxodotreotide (

methodsWe recruited Japanese patients from the Phase I and Phase I/II clinical trials. Patients received four infusions of 7.4 GBq

resultsTwenty-one patients (median age, 57 years) were recruited. The primary tumor sites included the pancreas (n=11), small intestine (n=5), rectum (n=2), lungs (n=2), and stomach (n=1). Twenty (95.2%) patients had liver metastases, whereas 19 (90.5%) had grade 2 tumors. The median PFS period was 36.6 months; median OS period was not　reached. Two (9.5%) patients achieved a complete response, 12 (57.1%) achieved a partial response, six (28.6%) had stable disease, and one (4.8%) had progressive disease. One patient had chronic myeloid leukemia 15 months post-PRRT.

conclusionsPRRT demonstrated sustained efficacy and safety in Japanese patients with NET.

Indexed as

Neuroendocrine TumorsReceptors, PeptideSafetySomatostatinAdultAgedEast Asian PeopleFemaleHumansJapanMaleMiddle AgedTime FactorsTreatment OutcomeReceptors, PeptideSomatostatinJapanNeuroendocrine tumorsPeptide receptor radionuclide therapy

Identifiers

PMID41678086
PMCPMC13219169

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.